Compare IT & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IT | HALO |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | 40 | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 8.8B |
| IPO Year | 2010 | 2001 |
| Metric | IT | HALO |
|---|---|---|
| Price | $150.35 | $66.47 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $189.25 | $78.64 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.18 | 2.56 |
| Revenue | ★ $2,021,441,000.00 | $151,862,000.00 |
| Revenue This Year | $3.52 | $28.24 |
| Revenue Next Year | $5.08 | $12.56 |
| P/E Ratio | $47.26 | ★ $25.74 |
| Revenue Growth | ★ 13.30 | N/A |
| 52 Week Low | $139.18 | $47.50 |
| 52 Week High | $451.73 | $82.22 |
| Indicator | IT | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 51.34 |
| Support Level | $142.76 | $63.85 |
| Resistance Level | $162.87 | $68.00 |
| Average True Range (ATR) | 5.60 | 1.95 |
| MACD | 0.18 | -0.05 |
| Stochastic Oscillator | 42.14 | 46.22 |
Gartner Inc delivers actionable, objective business and technology insights that drive smarter decisions and stronger performance on an organization's mission-critical priorities. It delivers its products and services globally through three reportable segments - Business and Technology Insights, Conferences and Consulting. Insights equips executives and their teams from every Majority function, geography, industry and sector with actionable, objective insights, guidance and tools. Conferences provides executives and teams across an organization the opportunity to learn, share and network. and Consulting serves senior executives technology-driven strategic initiatives leveraging the power of Gartner's actionable, objective insight. The Majority revenue is derived from the Insights segment.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.